Symposium – Fonds HIV Ontrafelen

HIV CURE SYMPOSIUM 2022

Welcome

The HIV Cure Research Center Ghent is very pleased to invite you to the 8th HIV Cure Symposium that will be held in the beautiful city of Ghent, Flanders, Belgium on September 12-13, 2022.

The HIV Cure Symposium will comprehensively summarize the state of the art in HIV cure strategies and diagnostic tools to monitor therapeutic interventions.
Distinguished speakers such as Marcus Buggert, Mathias Lichterfeld, Ya-Chi-Ho, Nicolas Chomont, Javier Martinez-Picado, John Frater, Rafick Sékaly, Ole Søgaard, Sarah Fidler, Marion Pardons, Tine Struyve, Evy Blomme, Casper Rokx and Jozefien De Clercq will highlight the latest developments and progress in HIV Cure research. We will discuss key topics: single cell approaches, the HIV reservoir, acute seroconversion and HIV cure strategies.

Program

Time Zone: Central European Summer Time (CEST)

Monday, September 12, 2022
12.00-13.00	Registration
13.00-13.10	Welcome and Introduction
13.10-14.55	SINGLE CELL APPROACHES TO IDENTIFY HIV RESERVOIRS Chaired by Zeger Debyser and Sarah Gerlo
13.10-13.35	How memory T cells recognize and eliminates viral infections Marcus Buggert, Karolinska Institute, Stockholm, Sweden
13.35-14.00	Novel single-cell assays for profiling HIV-1 reservoir cells Mathias Lichterfeld, Brigham and Women’s Hospital and Ragon Institute of MGH, MIT and Harvard, Boston, United States
14.00-14.25	Single-cell multi-omics understanding of HIV-induced immune dysfunction Ya-Chi Ho, Yale University, New Haven, United States
14.25-14.35	A01 - Multi-omics analysis reveals monocytes as drivers of persistent inflammation in chronic HIV Rainer Knoll, University of Bonn, Bonn, Germany
14.35-14.45	A02 - Anti-PD-1 therapy drives rapid induction of innate interferon and effector CD8 responses associated with HIV reservoir decay Ashish Sharma, Department of Pediatrics, Emory University, Atlanta, United States
14.45-14.55	A03 - Single virus imaging of HIV-1 nuclear import Anayat Bhat, KU Leuven, Leuven, Belgium
14.55-15.20	Break
15.20-16.40	THE TRANSLATIONAL COMPETENT RESERVOIR Chaired by Mathias Lichterfeld and Ya-Chi-Ho
15.20-15.45	The phenotype of T cells with intact HIV genomes Nicolas Chomont, Université de Montréal, Montréal, Canada
15.45-16.10	Potent latency reversal enables in-depth transcriptomic analyses of the translation-competent HIV reservoir Marion Pardons, HIV Cure Research Center, Ghent University, Belgium
16.10-16.20	A04 - Role of UHRF1 in HIV-1 transcriptional regulation Maryam Bendoumou, Université Libre de Bruxelles (ULB), Gosselies, Belgium
16.20-16.30	A05 - Single cell chromatin measurements enable prediction of HIV-1 latency reversal Peter Svensson, Karolinska Institutet, Stockholm, Sweden
16.30-16.40	A06 - New horizons for BRD4-modulators in a block-and-lock functional cure for HIV-1 Eline Pellaers, KU Leuven, Leuven, Belgium
16.40-17.00	Break
17.00-17.30	SATELLITE VIIV HEALTHCARE Chaired by Linos Vandekerckhove
17.00-17.30	Prospects for an HIV Cure – The ViiV Perspective Jan van Lunzen, Head of Translational Medical Research - ViiV Research & Development, London, United Kingdom
17.30-18.15	COLLABORATIVE CURE EFFORTS Chaired by Linos Vandekerckhove
17.30-17.45	Concerted action towards an HIV cure in Europe: EU2CURE Casper Rokx, Erasmus MC, Rotterdam, the Netherlands
17.45-18.00	2000HIV study: multi-omics analysis in 2000 PLHIV using long-term cART Andre van der Ven, Radboudumc, Nijmegen, the Netherlands
18.00-18.15	Reversing Immune Dysfunction for HIV-1 eradication (RID-HIV) Rafick-Pierre Sekaly, Department of Pathology, and Laboratory Medicine, Emory University, School of Medicine, Atlanta, United States
18.15-19.30	NETWORK RECEPTION

Tuesday, September 13, 2022
08.00-09.00	Registration
09.00-10.20	HOW TO QUANTIFY THE VIRAL RESERVOIR IN HIV CURE STUDIES Chaired by Ole Søgaard and John Frater
09.00-09.25	The multitask efforts of measuring viral persistence Javier Martinez-Picado, ICREA Research Professor at IrsiCaixa Research Institute, Associate Professor at the University of Vic , Barcelona, Spain
09.25-09.50	Setting up a high throughput pipeline to measure the intact proviruses Evy Blomme, HIV Cure Research Center, Ghent University, Belgium
09.50-10.00	A07 - Long-read sequencing assay allows accurate characterization of the HIV-1 reservoir Laurens Lambrechts, Ghent University, Ghent, Belgium
10.00-10.10	A08 - Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA Irene González, IrsiCaixa AIDS Research Institute, Barcelona, Spain
10.10-10.20	A09 - Natural Killer cells induce HIV-1 reactivation from latency after treatment with pan-caspase inhibitors Robert van Domselaar, Karolinska Institutet, Stockholm, Sweden
10.20-10.40	Break
10.40-12.00	ACUTE HIV INFECTION: LESSONS LEARNED SO FAR Chaired by Nicolas Chomont and Carine Van Lint
10.40-11.00	In-situ characterization of HIV reservoir microenvironments and inflammatory milieu in lymphoid tissues of patients treated during acute HIV infection Jozefien De Clercq, Ghent University, Ghent, Belgium
11.00-11.20	Characterization of the HIV reservoir in patients treated during acute HIV infection Tine Struyve, Ghent University, Ghent, Belgium
11.20-11.30	A10 - Treatment interruption and T cell immunity in ART-treated primary HIV infection Timothy Liong Tipoe, University of Oxford, Oxford, United Kingdom
11.30-11.40	A11 - Impact of pathogen-induced inflammation on the function and metabolic status of effector CD8 T cells Bram Van Den Eeckhout, Ghent University, Ghent, Belgium
11.40-11.50	A12 - Novel dual mechanism of action of natural occurring anti-HIV-1 dipeptide Rafael Ceña Diez, Karolinska Institutet, Stockholm, Sweden
11.50-12.00	A13 - HIV-2 triggers a cGAS-dependent type I interferon response in CD4+ T cells Marija Janevska, Ghent University Hospital, Ghent, Belgium
12.00-13.30	Lunch
13.30-13.50	PATIENTS PERSPECTIVES Chaired by Linos Vandekerckhove
13.30-13.50	Patient perspectives on HIV Cure in Europe Giulio Maria Corbelli, European AIDS Treatment Group (EATG)
13.50-17.00	REACHING AN HIV CURE Chaired by Linos Vandekerckhove and Javier Martinez-Picado
13.50-14.15	T-cell immunity in the context of bNAbs and the search for a vaccinal effect John Frater, University of Oxford, England, United Kingdom
14.15-14.40	Convergent immune based approaches to the Control of viral rebound post ATI Rafick-Pierre Sekaly, Department of Pathology, and Laboratory Medicine, Emory University, School of Medicine, Atlanta, United States
14.40-14.50	A14 - The BAF complex inhibitor pyrimethamine induces HIV-1 transcription in ART-suppressed HIV-1-infected individuals Raquel Crespo, University Medical Center Rotterdam, Rotterdam, The Netherlands
14.50-15.00	A15 - Potent antiviral activity of novel HIV-1 maturation inhibitors in human primary macrophages and lymphocytes Leonardo Duca, University of Rome, Rome, Italy
15.00-15.10	A16 - Relevance of HIV-1 RNA stabilization and degradation mechanisms linked to MATR3 and EXOSC10 during reactivation from latency Agnieszka Suder, Jagiellonian University, Krakow, Poland
15.10-15.40	Break + poster session
15.40-16.05	HIV cure interventions at the time of ART initiation Ole Søgaard, Aarhus University Hospital, Aarhus, Denmark
16.05-16.30	Current ongoing bNAbs studies in the UK Sarah Fidler, Imperial College London and Imperial College NHS Trust, London, United Kingdom
16.30-16.40	A17 - Broadly neutralizing antibodies secreted by CAR T cells impair HIV infectivity Wojciech Witkowski, Ghent University, Ghent, Belgium
16.40-16.50	A18 - Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors Martin V. Hamann, Leibniz Institute for Experimental Virology and German Center of Infection Research, Hamburg, Germany
16.50-17.00	A19 - SIV Elite control is induced upon dual IL-10 and PD-1 Blockade in SIVmac239 infected Rhesus macaques Susan P. Ribeiro, Emory University, Atlanta, USA
17.00-17.10	CLOSING REMARKS

Registration

Call for abstracts

The HIV Cure Research Center invites you to submit abstracts for oral presentations for the HIV Cure Symposium to be held on 12-13 September 2022 in Ghent. The length of abstracts for presentations should not exceed 350 words. Ten minutes will be foreseen for each selected poster presentation.

The deadline for abstract submission is July 22, 2022. Notification of acceptance will be made on July 30th 2022. Please send abstracts as a Pdf document to Linos Vandekerckhove, linos.vandekerckhove@ugent.be by July 30th.

Venue

The HIV Cure Symposium will take place in Auditorium Oehoe, Building E1, Coupure Links, Gent, Belgium

How to get there:

From Sint-Pietersstation – Auditoriom Oehoe: 2.3 km

From the station you can take tram 2 or 4 at platform 20, stop Rozemarijnbrug, 5 min walk to Auditorium Oehoe.

Organizing Committee

Prof. Dr. Linos Vandekerckhove – Head of the HIV Cure Research Center – Ghent University Belgium

Prof. Dr. Sarah Gerlo – PI HIV Cure Research Center – Ghent University – Belgium

Prof. Zeger Debyser – Heaed of the Molecular Virology and Gene Therapy Unit – KU Leuven – Belgium

Karen Vervisch – Lab Manager – Ghent University Hospital – Belgium

2021 in preview

Interested in re-watching the 2021 HIV Cure and SARS-CoV-2 Hybrid Symposium that was held in Zellik, Belgium?

Contact

Karen Vervisch
Karen.vervisch@uzgent.be
+32 (0) 9 332 94 25

Diamond Sponsors

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Iron Sponsors

WERELDWIJD LEVEN 37 MILJOEN MENSEN MET HIV. STEUN HET FONDS HIV ONTRAFELEN en Help hen.

Door de COVID-19 maatregelen zal de 7de editie pas in december 2022 plaatsvinden.

Doe een online gift

Doneer hier!